YoungSolvers

Next Generation of Drug Designers

Young scientists are the future. Their success is determined by encouragement of the scientific community, the accessibility to knowledge, and the right tools to apply it.
'YoungSolvers' aims to support individual master thesis projects in Europe with a free-of-charge two month license for our software. With this we encourage independent creative research conveniently from home.

Profit from BioSolveIT's
drug discovery package

SeeSAR 3D desktop molecular modeling platform

SeeSAR

SeeSAR is a user-friendly drug design platform. Start from a small fragment-binder and evolve it to full-fledged drug candidate, screen libraries to predict active binders, or work interactively with a known binder to increase it's affinity. SeeSAR offers all the tools to support drug discovery beginners and veterans alike.
For more information read the SeeSAR PDF.
infiniSee screening platform

infiniSee

infiniSee is a navigation platform to find similar molecules in Chemical Spaces. Start with an active query molecule and search for distant neighbours for your target. The twist behind it: all molecules are accessible and can be purchased or easily synthesized by yourself.
For more information read the infiniSee PDF.
Knime icon big

Knime Workflows

KNIME is a modular, extendable data exploration platform to visually create workflows. The provided BioSolveIT workflows (FragXplorer, REALizer, BioSphere, MedChemWizard) themselves are easily adjustable to your project and can be a great help to set up your project.

Profit from BioSolveIT's
drug discovery package

Once you got access to our software, you can benefit from several educational BioSolveIT services. We offer virtual workshops on our software and applications, as well as a variety of tutorials and short-educational videos.

Help

FAQ

To apply for YoungSolvers you need to provide:
  • Official confirmation of your status as a Masters student (e.g. student ID, enrollment at university)
  • Filled-out form signed by your supervisor
Send both in a single PDF to youngsolvers@biosolveit.de.

Please note: As of today, BioSolveIT is happy to support Master students at European Universities only. Depending on acceptance, potential legal constraints, and other factors, the concept may be extended to other areas in the world in the future.
No. Our YoungSolvers licenses come with no strings attached. We explicitly do not claim any rights on intellectual proprietary resulting from the master thesis. Also, there are no license fees. For two months you will get free access to the applications and workflows. We want to provide our state-of-the-art software to young scientist to encourage them in their research without any monetary gain.
Our Scientific Challenge Winners have contributed many successful stories with our software. You may find some ideas to implement in your project there.
We offer interactive workshops for YoungSolvers to support them with their project. The workshops will be recorded and can be accessed afterwards on youtube. If the workshop is of interest to you, you can participate even as a non-member of YoungSolvers.
  • Introduction to SeeSAR and infiniSee (Recording)
  • From Fragment to Drug Candidate with SeeSAR (Recording)
  • Stumbling Blocks in Drug Design - Applied Medicinal Chemistry (Recording)
Once you received your approval confirmation, you need to confirm your license request one week (7 days) ahead of the beginning of the license. With this we offer a flexible starting date of the license in case of delays.
Simply send an informal request seven days ahead to youngsolvers@biosolveit.de.

Case Example 1
Fragment Evolution

Start with a small fragment binder (e.g. PDB-ID: 3OOG) with the working hypothesis to design more potent derivatives. Use SeeSAR to describe and analyze the binding site, discover unnoccupied cavities, and prepare high-quality visuals. Important structural contributions of the ligand to it's affinity can be characterized with the implemented HYDE affinity estimation to generate ideas where optimizations can be made. Add functional groups or whole substructures to further increase the potency of your ligand. Once you are done, you can check if your drug candidates can be easily synthesized in the virtual KnowledgeSpace with infiniSee.

Case Example 2
Scaffold Hopping

You start with a molecule that contains an unwanted motif (e.g. toxic, unfavorable physico-chemical properties, patent-protected). With SeeSAR you can design new molecules or replace whole scaffolds with the ReCore functionality of the Inspirator Mode. The designed molecules can further be characterized for their physico-chemical properties (log P, solubility, lipophilic ligand efficiency, ...) as well as their toxicologic profile (hERG IC50, P-gp, ability to penetrate the blood brain barrier, ...). Additionally, you can perform a fuzzy similarity search with infiniSee to find novel, accessible models in our Chemical Spaces and assess those for their safety profiles.
"A Gaze into Chemical Space" Series
April 16, 2024 11:26 CEST
Introducing our latest series, “A Gaze into Chemical Space,” where we explore the expansive realms of combinatorial compound collections. Our aim in this exercise is to uncover similar compounds of potential and approved drugs using various methods. Typically, several synthesis steps are required to get to a compound with favorable...
Read on
Behind the Scenes of Enamine's REAL Space
April 15, 2024 16:43 CEST
Since its launch in 2018, Enamine’s REAL Space has made a significant impact in revolutionizing the landscape of compound collections. The initial version contained approximately 650 million compounds, establishing itself as one of the expansive catalogs of commercially available molecules for drug discovery. Notably, the first release rivaled even the...
Read on
category
Webinars
A Novel Class of SARS-CoV-2 Mpro Inhibitors: Systematic Design, Synthesis, Biological Evaluation, Antiviral Activity, and Structural Insights
Thu, 25 Apr 2024, 16:00 CEST (Berlin)
COVID-19 is shifting from pandemic to endemic, but the etiological agent, SARS-CoV-2, is still spreading and causing public health issues around the world. New variants, with multiple mutations in their spike proteins, are now able to evade neutralization by antibodies in vaccinated and convalescent individuals. Consequently, there is a pressing...
Read on